10-Q: Pulse Biosciences Reports Q2 2024 Results, Focuses on Atrial Fibrillation and Soft Tissue Ablation

Pulse Biosciences' Q2 2024 report highlights a continued focus on developing its nsPFA technology for atrial fibrillation and soft tissue ablation, with no revenue reported and ongoing operating losses.

Summary

• Pulse Biosciences reported its financial results for the second quarter of 2024, showing no revenue and a net loss of $11.383 million.
• The company's research and development expenses increased to $7.230 million for the quarter, up from $6.697 million in the same period last year.
• General and administrative expenses also rose to $4.496 million, compared to $3.530 million in Q2 2023.
• The company's cash and cash equivalents stood at $26.196 million as of June 30, 2024, down from $44.365 million at the end of 2023.
• Pulse Biosciences is focusing on the development of its CellFX System for atrial fibrillation (AF) and soft tissue ablation, with ongoing clinical studies and regulatory submissions.
• The company completed a rights offering in July 2024, raising $60 million in gross proceeds.
• The company has received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation and a second size of the percutaneous electrode needle.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as FDA clearances and a successful capital raise, the company's ongoing losses, lack of revenue, and dependence on future product development create significant risks. The sentiment is cautiously negative due to the financial challenges and development uncertainties.

Positives

• The company received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation, allowing for commercialization in the US.
• The company completed a rights offering in July 2024, raising $60 million in gross proceeds, which will help fund operations.
• The company received Breakthrough Device Designation from the FDA for its CellFX nsPFA Cardiac Surgery System for the treatment of AF, which may expedite the regulatory process.
• The company has expanded its clinical study for its cardiac catheter in Prague to enroll up to 60 patients.
• The company has initiated a first-in-human clinical study in the Netherlands for its cardiac surgical ablation clamp.

Negatives

• The company reported a net loss of $11.383 million for Q2 2024, indicating ongoing financial challenges.
• The company has not generated any revenue for the three and six month periods ended June 30, 2024.
• Cash and cash equivalents decreased significantly from $44.365 million at the end of 2023 to $26.196 million as of June 30, 2024.
• The company's operating expenses, including research and development and general and administrative costs, have increased compared to the same period last year.

Risks

• The company is a development-stage company with limited commercialization experience and has incurred significant losses since inception.
• The company's future success depends heavily on the successful development and commercialization of its NPS technology, particularly for atrial fibrillation and soft tissue ablation.
• The company faces substantial competition from well-established medical device companies.
• The company's ability to obtain regulatory approvals for its product candidates is subject to uncertainty and potential delays.
• The company may need to raise additional capital in the future, which may result in dilution to existing investors or incur additional indebtedness.
• The company's products may cause serious adverse side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial desirability.
• The company's intellectual property rights may not provide adequate protection against competitors.
• The company is subject to cybersecurity and data privacy threats and incidents, which could have a material adverse effect on its business.
• The company's Executive Chairman owns a majority of the voting power of the outstanding shares of common stock, which may limit the ability of other investors to affect corporate governance or major decisions.

Future Outlook

The company plans to pursue more clinical evidence-based milestones throughout 2024 and into 2025 in connection with evaluating the early pilot commercialization of its percutaneous electrodes, and expects to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules. The company also expects to begin its pivotal clinical trial for AF in 2025.

Management Comments

• Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the CellFX platform in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation.
• We expect to pursue more clinical evidenced-based milestones throughout 2024 and into 2025 in connection with evaluating the early pilot commercialization of our percutaneous electrodes, and we expect to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules.
• We expect to begin our pivotal clinical trial for AF in 2025.

Industry Context

The company's focus on atrial fibrillation and soft tissue ablation aligns with growing trends in the medical device industry, where minimally invasive procedures and advanced ablation technologies are gaining traction. The company is competing with established players in the cardiac ablation market, including Abbott, Boston Scientific, and Medtronic, all of whom are also developing PFA products for the treatment of AF.

Comparison to Industry Standards

• Pulse Biosciences is competing in the cardiac ablation market with companies like Abbott Laboratories, AtriCure, Inc., Boston Scientific Corporation, Johnson & Johnson (Biosense Webster), and Medtronic plc, all of whom have greater financial and technical resources.
• The company's focus on nsPFA technology is a differentiator from traditional thermal ablation methods, but it is also competing with companies developing pulsed field ablation (PFA) technologies, such as micro-PFA.
• The company's lack of revenue and ongoing losses are typical for a development-stage medical device company, but it will need to demonstrate commercial viability to compete effectively with established players.
• The company's recent FDA clearances for its percutaneous electrode system are a positive step, but it will need to generate clinical data and market adoption to achieve commercial success.
• The company's reliance on a single platform technology (NPS) and a single family of products (CellFX) is a risk compared to companies with more diversified product portfolios.

Legal Proceedings

• The company is involved in an arbitration demand with its former Chief Financial Officer, Sandra Gardiner, seeking severance benefits and other remedies. The company believes the claims are without merit and intends to defend itself vigorously.

Related Party Transactions

• The company entered into a Securities Purchase Agreement with Robert W. Duggan, the company's majority stockholder and Executive Chairman, in April 2023, resulting in the issuance of 10,022,937 shares of common stock in exchange for the cancellation of a $65 million loan and accrued interest.
• Robert W. Duggan purchased approximately 56% of the shares offered through the 2022 Rights Offering.
• Robert W. Duggan purchased approximately 88% of the shares offered through the 2024 Rights Offering.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and potential losses due to the company's ongoing operating losses.
• Employees may be affected by potential restructuring or headcount reductions if the company fails to secure adequate funding.
• Customers (surgeons and other physicians) may benefit from the company's innovative technologies, but adoption may be slow due to the need for training and clinical evidence.
• Suppliers may be impacted by the company's financial performance and ability to pay for components and materials.
• Creditors may be at risk if the company is unable to secure additional funding or generate revenue.

Next Steps

• The company plans to pursue more clinical evidence-based milestones throughout 2024 and into 2025 in connection with evaluating the early pilot commercialization of its percutaneous electrodes.
• The company expects to commence a pivotal clinical trial in 2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules.
• The company expects to begin its pivotal clinical trial for AF in 2025.
• The company will continue to develop its cardiac surgical ablation clamp and cardiac endocardial ablation catheter.

Key Dates

Keywords

Pulse Biosciences, Nano-pulse Stimulation, nsPFA, CellFX System, atrial fibrillation, soft tissue ablation, cardiac ablation, medical devices, clinical trials, FDA clearance, rights offering